Dr. Pui on Utilizing CAR T-Cell Therapy in Pediatric ALL

Ching-Hon Pui, MD, discusses the use of CAR T-cell therapy in patients with relapsed/refractory acute lymphocytic leukemia.

Ching-Hon Pui, MD, chair, Oncology Department, St. Jude Children's Research Hospital, discusses the use of CAR T-cell therapy in patients with relapsed/refractory acute lymphocytic leukemia (ALL).

CAR T-cell therapy is currently used in pediatric patients with relapsed/refractory ALL. Increasingly, it is used to treat patients with central nervous system relapsed or testicular relapse, says Pui.

In the past, pediatric patients with ALL required radiation to be cured; however, now CAR T-cell therapy can cure those patients without the use of radiation. Pui believes that in the near future, CAR T-cell therapy will be used to treat patients with high-risk ALL and avoid intensive chemotherapy altogether, improving the patient's quality of life as well as the cure rate.

Related Videos
Binod Dhakal, MD, on Assessing Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma
Brian Van Tine, MD, PhD, on Further Research With Cell Therapy in Synovial Sarcoma
Brian Van Tine, MD, PhD, on Continued Durability of Afami-Cel in Synovial Sarcoma
Thomas McCauley, PhD, on Treating Solid Tumors With Epigenomic Controllers
Rebecca Cottman, PhD, on Creating Regulated Gene Circuits to Enhance Cell Therapy Cytotoxicity
John Leonard, PhD, on an AAV Approach to Exon 51 Skipping in DMD
Joseph Fraietta, PhD, on Investigating Molecular Pathways of CAR T-Cell Resistance
© 2023 MJH Life Sciences

All rights reserved.